Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2023 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

Trial designed with pre-specified primary efficacy endpoints discussed previously with FDAIf successful, this phase 2 trial may serve as one of the two required phase 3 studies necessary to support...
April 25, 2023 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
April 05, 2023 02:00 ET | Source: OKYO Pharma LTD

Notice of General Meeting and Publication of Circular

LONDON and NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is...
April 04, 2023 02:00 ET | Source: OKYO Pharma LTD

Notice of Intention to Delist From The London Stock Exchange

LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is...
March 30, 2023 02:01 ET | Source: OKYO Pharma LTD

OKYO Pharma Today Announces Director Acquires Shares

LONDON and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
March 29, 2023 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Today Announces Director Acquires Shares

LONDON and NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
March 24, 2023 03:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces PDMR Dealing

LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
March 16, 2023 03:01 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
March 14, 2023 03:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER...
March 13, 2023 16:15 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

LONDON, March 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel...